Ohsu Knight Cancer Institute
Clinical trials sponsored by Ohsu Knight Cancer Institute, explained in plain language.
-
New chemo combo targets Hard-to-Treat liver cancer
Disease control TerminatedThis early-phase trial tested a two-step chemotherapy approach for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. First, patients received a standard chemo mix (mFOLFIRINOX) through the veins. Then, they got a second chemo …
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Tailored cancer therapy put to the test
Disease control TerminatedThis study tested a precision medicine approach for people with advanced cancers like breast, ovarian, pancreatic, prostate, or sarcoma. Researchers used genetic and protein tests to track how the cancer changes and then a team of experts recommended personalized drugs. The goal …
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Can smartphone cameras spot skin cancer as well as a dermatologist?
Diagnosis TerminatedThis study tested three portable imaging systems (MoleMapper, Visiomed, and confocal microscopy) to see how well they could detect melanoma compared to a dermatologist's exam. Seventeen people with suspicious moles participated. The goal was to find out if these devices could acc…
Phase: NA • Sponsor: OHSU Knight Cancer Institute • Aim: Diagnosis
Last updated Jun 27, 2026 12:05 UTC
-
AI mole checker tested at home – but trial stops early
Diagnosis TerminatedThis study tested whether a device called the Sklip System, which uses artificial intelligence, could help people at home decide if a mole might be skin cancer. Only one person took part before the study was stopped early. The goal was to see if the AI could match or beat standar…
Phase: NA • Sponsor: OHSU Knight Cancer Institute • Aim: Diagnosis
Last updated Jun 27, 2026 08:07 UTC
-
New MRI technique aims to solve brain tumor treatment mystery
Diagnosis TerminatedThis pilot study tested whether a special MRI using ferumoxytol (an iron-based contrast agent) can better distinguish true tumor growth from treatment-related inflammation (pseudoprogression) in people with glioblastoma receiving the immunotherapy drug pembrolizumab. The study en…
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Diagnosis
Last updated Jun 26, 2026 15:10 UTC